PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: CompaniesAndMarkets.com

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Global Ovarian Cancer Drugs Market to Reach $2,352 Million by 2020 Finds CompaniesAndMarkets.com - The global ovarian cancer drugs market has been anticipated to triple over the next decade as a number of pipeline candidates enter the industry and are set to change treatment programs - CompaniesAndMarkets.com
Global Ovarian Cancer Drugs Market to Reach $2,352 Million by 2020 Finds CompaniesAndMarkets.com

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/09/11 - The global ovarian cancer drugs market has been anticipated to triple over the next decade as a number of pipeline candidates enter the industry and are set to change treatment programs - CompaniesAndMarkets.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The global ovarian cancer drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 13.1% over the period through to 2015.

In 2011, the ovarian cancer drugs markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7 million collectively.

The ovarian cancer drugs market is expected to witness three-fold growth by 2020, reaching $2,352 million at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

Key factors contributing to growth within the industry include the increasing prevalence of ovarian cancer and the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market.

The current trend occurring in the global ovarian cancer drugs market is the use of combination therapies for the treatment of ovarian cancer.

Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy.

Therefore, combination therapies help in the complete removal of tumours and the destruction of cancerous cells. The combination is chosen according to the size of the tumour and the risk of recurrence.

The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market.

The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011-2020.

Key players dominating the global ovarian cancer drugs market include Eli Lilly and Co., GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: CompaniesAndMarkets.com

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Global Ovarian Cancer Drugs Market to Reach $2,352 Million by 2020 Finds CompaniesAndMarkets.com

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Mike King - CompaniesAndMarkets.com 
+44(0)20 3086 8600
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any CompaniesAndMarkets.com securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From CompaniesAndMarkets.com / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)